Key result
Lower lymphocyte-to-monocyte ratio (OR 0.659, P<0.01) and higher monocyte-to-HDL-C ratio (OR 1.174, P=0.04) independently predicted slow flow/no-reflow in NSTEMI patients undergoing PCI.
Why the study?
It was unclear whether inflammation-based scores, including NLR, PLR, LMR, and MHR, predict the slow flow/no-reflow phenomenon comparatively in patients with NSTEMI undergoing PCI.
Do inflammation-based scores (LMR and MHR) predict the slow flow/no-reflow phenomenon in NSTEMI patients undergoing PCI?
Population
426 NSTEMI patients undergoing PCI
Comparison
Slow flow/no-reflow vs non slow flow/no-reflow groups
Design
Retrospective study
Authors
Loading...
May aid SF/NR risk stratification in NSTEMI PCI; leaves open clinical utility pending prospective validation.
Observational (n=426)
Do inflammation-based scores (LMR and MHR) predict the slow flow/no-reflow phenomenon in NSTEMI patients undergoing PCI?
Odds Ratio: 0.659
p-value: p=<0.01
LMR and MHR are useful inflammatory biomarkers for predicting the development of slow flow/no-reflow in NSTEMI patients undergoing PCI.
Kalyoncuoğlu et al. (2020) conducted an observational in Non-ST-elevated Myocardial Infarction (NSTEMI) (n=426). Lymphocyte-to-monocyte ratio (LMR) and monocyte-to-HDL-C ratio (MHR) vs. Non slow flow/no-reflow group was evaluated on Slow flow/no-reflow phenomenon (OR 0.659, p=<0.01). Lower lymphocyte-to-monocyte ratio (OR 0.659, P<0.01) and higher monocyte-to-HDL-C ratio (OR 1.174, P=0.04) independently predicted slow flow/no-reflow in NSTEMI patients undergoing PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: